FL-1NCE
13.12.2022 14:16:39 CET | Business Wire | Press release
1NCE, a global IoT connectivity and software company, has won two major awards – earning a place on Fast Company’s Next Big Things in Tech list and a first prize finish at Light Reading’s Leading Lights.
At Fast Company’s 2nd annual Next Big Things in Tech awards, which celebrate technology breakthroughs that promise to shape the future of industries, 1NCE received an Honorable Mention in the Enterprise category “for making Internet of Things connectivity ubiquitous and affordable.” According to Fast Company, the awards “showcase new, groundbreaking technology or reveal an innovative application for existing tech.”
The majority of IoT projects require multinational deployments, but few mobile network operators have the capability to meet cross-border demands. The 1NCE Lifetime Flat service is industry-disruptive but simple: for $10/€10, customers can deploy, connect, and manage IoT sensors across the world for as little as a dollar per year per device. More than 10,000 customers worldwide already trust 1NCE with more than 15 million managed connections.
At Light Reading’s 18th annual Leading Lights awards, 1NCE and Flashnet, a leader in intelligent energy management systems, won the top prize for Outstanding Use Case in Innovative IoT – which is “awarded to the service provider or vendor helping change businesses and improve customer experiences with innovative Internet of Things devices and services.”
For decades, Washington DC’s lighting system, covering more than 1,500 miles of streets, has used high energy-consuming sodium lamps that require manual monitoring and reporting – and are serviced through a time-consuming, high-cost effort made vulnerable to human error and oft-intense weather. Flashnet and 1NCE teamed up to illuminate the nation’s capital using half the energy previously used at considerably lower operating expense. More remarkably, it’s a one-time job. Flashnet integrated 1NCE’s connectivity and software directly into the smart city network with a telecommunication control unit (TCU) specially designed to instantly tap into existing light bulbs and poles – controlled and monitored from a distance. Combining immense supply chain benefits, long-term energy-efficiency, reduced human error, lower risk of utility worker injuries, future-proof design and comprehensive monitoring/management tools, Flashnet has built a smart city solution on the 1NCE platform that can be used by cities large and small, around the world.
“2022 was a huge year of change and growth for 1NCE, and winning recognition from these two prestigious programs is validation of the hard work our team has done to deliver easy, affordable IoT connectivity and software across any border,” said Ivo Rook, Chief Operating Officer at 1NCE. “And to receive an award together with our amazing partners at Flashnet emboldens us to continue working hard to disrupt IoT and assist smart cities in meeting the unique challenges of our times.”
The Fast Company and Leading Lights awards cap a successful 2022 for 1NCE, which also won at the IoT Evolution Product of the Year Awards and was named Best in Show at Embedded World. The company also expanded to its 153rd country, after starting the year at 106.
New customers can get started with 1NCE at the company’s online shop and the AWS Marketplace.
About 1NCE
1NCE is the only connectivity and software company providing IoT at a global lifetime flat rate. Its mission is to deliver true cross-border, future-proof IoT without uncertainty or hassle over the lifetime of a device. In 150+ countries, 1NCE turns connectivity into electricity ready for consumption – opening the world of IoT to innovators who will dramatically improve the environment, cities, healthcare, public safety, the supply chain and more. The company, founded in 2017 by CEO Alexander P. Sator together with Deutsche Telekom AG, is headquartered in Cologne, Germany and has 250+ staff across 20 countries. Learn more online and follow 1NCE on Twitter, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom